The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy

C Bal; S Korn; K Milger-Kneidinger; D Skowasch; C Schulz; S Zehetmayer; C Taube; E Hamelmann; R Buhl; M Idzko

doi:10.1055/s-0043-1760974

Pneumologie, Inhaltsverzeichnis

Pneumologie 2023; 77(S 01): S45
DOI: 10.1055/s-0043-1760974

Abstracts

The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy

Authors

C Bal

¹Division of Pulmonology, Department of Internal Medicine II, Medical University Vienna, Austria
S Korn

²Thoraxklinik Heidelberg; Ikf Pneumologie Mainz
K Milger-Kneidinger

³Department of Medicine V, LMU University Hospital Munich; Comprehensive Pneumology Center (Cpc-M), Member of the German Center for Lung Research (Dzl); Medizinische Klinik V
D Skowasch

⁴Uniklinikum Bonn; Medizinische Klinik Ii; Kardiologie, Pneumologie
C Schulz

⁵Klinik und Poliklinik für Innere Medizin Ii; Pneumologie; Department of Internal Medicine II, University Hospital Regensburg, Regensburg
S Zehetmayer

⁶Department for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Austria
C Taube

⁷Universitätsklinikum Essen – Ruhrlandklinik; Klinik für Pneumologie; Pneumologie Universitätsmedizin Essen
E Hamelmann

⁸Klinik für Kinder- und Jugendmedizin Bielefeld; Universitätsklinikum Owl, Universität Bielefeld; Kinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld
R Buhl

⁹Universität Mainz; Med. Klinik; Schwerpunkt Pneumologie, III.
M Idzko

¹⁰Universitätsklinik für Innere Medizin Ii; Abteilung für Pulmonologie; Ebene 6/L

Abstract

Volltext

348 of 2283 patients with severe asthma>12 yrs. included in the real-life, long-term German Asthma Net registry used anti-IL5(R) antibody therapy (mepolizumab, benralizumab, reslizumab), (57±13 yrs., 57% female, BMI 27±6 kg/m², 5±5 exacerbations per year, ACQ score 2.6±1.5), compared to 329 corticosteroid (OCS) dependent patients (49±17 yrs., 55% female, BMI 27±6 kg/m², 4±4 exac./year, ACQ 2.6±1.4).

Abb. 1

Baseline ACQ, mAQLQ and FEV1 values were comparable, patients on IL5(R) received more OCS at baseline (6±11 vs 4±10 mg, p=0.021). In comparison to systemic corticosteroid dependent patients without biological therapy, patients on anti-IL5(R) therapy showed significantly better asthma control (ACQ-5 score), better quality of life (mAQLQ score), and an increase in FEV1 in% predicted (all mean+SD). OCS dependency (median [IQR]) was also significantly reduced:

Conclusion Real-life, severe asthma patients treated with anti-IL5(R) biologics showed long-term benefits regarding pivotal outcome and disease control parameters including asthma control, quality of life, lung function, and corticosteroid use, highlighting beneficial effects previously documented in controlled studies in a real-life severe asthma cohort. These effects appear to be superior to those obtained with OCS treatment.

Abbildungen

Abb. 1